Brimonidine Tartrate

Brimonidine tartrate is a topical alpha-2 adrenergic agonist used to lower intraocular pressure (IOP) in glaucoma and ocular hypertension. It reduces IOP by suppressing aqueous production and enhancing uveoscleral outflow, with effects peaking 2-3 hours post-instillation. Available formulations include 0.2%, 0.15%, and 0.1% solutions, with Purite-preserved versions offering better tolerability than benzalkonium chloride. Brimonidine effectively controls IOP as monotherapy or adjunctively, particularly with prostaglandins. It induces miosis, benefiting conditions like primary angle closure and pigment dispersion syndrome.

Brimonidine tartrate gel (0.33%) is the first topical treatment approved for facial erythema of rosacea. It is a highly selective alpha-2 adrenergic receptor agonist that causes direct vasoconstriction of small arteries and veins. In Phase III trials, once-daily application achieved significant improvement in erythema within 30 minutes, with effects lasting up to 12 hours. Responder rates (two-grade improvement on clinician and patient assessments) at day 29 were approximately 70% with brimonidine versus 30-40% with vehicle. A 12-month open-label study confirmed sustained efficacy and safety, with most adverse events occurring in the first month. Brimonidine can be combined with other rosacea treatments (e.g., metronidazole, azelaic acid, doxycycline) for patients with concurrent papules and pustules.